CA
RPRX icon

Cliff Asness’s Royalty Pharma RPRX Stock Holding History

Cliff Asness’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241M Buy
4,305,412
+523,374
+14% +$27.2M 0.08% 331
2026
Q1 		$180M Buy
3,782,038
+1,218,384
+48% +$53.4M 0.08% 333
2025
Q4 		$99.1M Buy
2,563,654
+602,568
+31% +$23M 0.05% 474
2025
Q3 		$69.2M Buy
1,961,086
+224,811
+13% +$8.14M 0.04% 516
2025
Q2 		$62.1M Sell
1,736,275
-871,815
-33% -$28.9M 0.05% 482
2025
Q1 		$80.4M Buy
2,608,090
+704,414
+37% +$22.3M 0.08% 330
2024
Q4 		$48.6M Buy
1,903,676
+1,240,384
+187% +$32.9M 0.06% 390
2024
Q3 		$18.7M Sell
663,292
-122,275
-16% -$3.39M 0.03% 647
2024
Q2 		$20.7M Buy
785,567
+320,606
+69% +$8.89M 0.03% 567
2024
Q1 		$14.1M Buy
464,961
+34,000
+8% +$1M 0.02% 608
2023
Q4 		$12.1M Sell
430,961
-204,722
-32% -$5.63M 0.02% 633
2023
Q3 		$17M Buy
635,683
+448,127
+239% +$13.3M 0.04% 518
2023
Q2 		$5.7M Buy
+187,556
New +$6.35M 0.01% 853

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cliff Asness's RPRX Position: Q2 2026 in Review

Cliff Asness increased its Royalty Pharma (RPRX) stake by 14% in Q2 2026, buying an estimated $27.2M and bringing the position to 4,305,412 shares worth $241M. The position accounts for 0.08% of the portfolio, ranked #331.

Cliff Asness first reported a position in RPRX in Q2 2023 and has held it in 13 quarters since. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cliff Asness held 4,305,412 shares of Royalty Pharma worth $241M as of Q2 2026.
  • Cliff Asness bought 523,374 Royalty Pharma shares in Q2 2026, an estimated $27.2M.
  • Royalty Pharma made up 0.08% of Cliff Asness's portfolio in Q2 2026, its #331 holding.
  • Cliff Asness first reported a position in Royalty Pharma in Q2 2023 and has held it in 13 quarters since.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.